Pfizer, in what could be the prelude to spinning off its generic drug business, said it plans to separate its commercial operations into two units, mainly for patent-protected brands and a third for generics.
Pfizer to split generic, branded drug units
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You
Sponsored Content